Project description
New device to help people with heart failure
Heart failure (HF) is a chronic condition where the heart cannot pump enough blood to support the needs of other organs in the body. In Europe, it is the leading cause of hospitalisation in people over the age of 65. An estimated 15 million people are living with HF in Europe. Hence, improving management and care for patients is a top priority. The EU-funded PICSOHF project is developing a breakthrough method that triggers myocardial regeneration. It consists of a percutaneous right heart catheter intervention using special software for feedback control, which temporarily elevates the pressure in cardiac veins, reactivating innate regeneration pathways. The patented technology is unique. No similar device is currently available.
Objective
Worldwide 26 million people live with HF (Heart Failure) which is a major burden, not only for the patient, but one that also threatens the sustainability of national healthcare systems. Despite advances in treatment solutions over the last 30 years, improvements have not met the expectations for cardiac recovery and prognosis following heart attack. Current treatments are only partial solutions as they cannot regenerate the damaged heart tissue, and are thus unable to stop the progressive loss of heart function, low short- and medium-term life expectancy, and impoverished quality of life due to co-morbidities and/or frequent and continuous re-hospitalisations.
Regenerative concepts, such as cellular therapies to regain cardiac function, once of the greatest hope for heart failure patients, have been recently discredited as they have been unable to show scientific proof of efficacy.
Miracor, developed and clinically tested PiCSO, a breakthrough cardiac intervention triggering myocardial regeneration. Our therapy consists of a percutaneous right heart catheter intervention using proprietary software for feedback control that temporarily elevates the pressure in cardiac veins reactivating innate regeneration pathways. We have tested PiCSO in chronic HF patients (8 patients versus 22 controls) and demonstrated that 30 minutes of intervention changed the pattern of regenerative biomarkers in cardiac veins that resulted in significantly improved survival at 10 years follow up.
Our patented technology (PiCSOHF ) is changing the market in HF, as no similar device is currently available. Our strategic goal is to become Europe´s leading reference in treating HF. After full technological, clinical and commercial development, PICSOHF profits will increase by +€66M within 5 years after commercial launch.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
4340 AWANS
Belgium
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.